[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"424 General Military Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100528747","sequential-therapies-after-osteoanabolic-treatment-100528747",false,"NCT06164795","Sequential Therapies After Osteoanabolic Treatment","Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide\u002FAbaloparatide (START) Study","START","Inclusion Criteria:\n\n• Postmenopausal women treated with severe osteoporosis completing their course with romosozumab or teriparatide\n\nExclusion Criteria:\n\n* a bone disease other than postmenopausal osteoporosis\n* use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study\n* creatinine clearance \\\u003C60 mL\u002Fmin\u002F1.73 m2\n* liver failure\n* any type of cancer\n* uncontrolled endocrine diseases\n* serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng\u002FmL (50 nmol\u002FL)\n* hypersensitivity to denosumab or zoledronate or teriparatide or romosozumab or any of the excipients","FEMALE","50 Years","85 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics",[26],"Osteoporosis, Postmenopausal","RECRUITING","2025-04-24",{"date":30,"type":31},"2025-04-27","ACTUAL",{"date":33,"type":31},"2023-11-25",{"date":35,"type":22},"2027-05",{"name":37,"class":38},"424 General Military Hospital","OTHER",8,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},"100483448","single-or-repeat-zoledronate-versus-alendronate-following-denosumab-european-denosumab-effects-consolidation-study-100483448","NCT05575167","Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","The Effectiveness of Single or Repeat Zoledronate Infusion Versus Oral Alendronate in Consolidating the Bone Accrual Achieved With Denosumab: a Study Organised by the European Calcified Tissue Society","EURODEC","Inclusion Criteria:\n\n• Postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia\n\nExclusion Criteria:\n\n* a bone disease other than postmenopausal osteoporosis\n* use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months before entering the study\n* creatinine clearance \\\u003C60 mL\u002Fmin\u002F1.73 m2\n* liver failure\n* any type of cancer\n* uncontrolled endocrine diseases\n* serum 25-hydroxy vitamin D (25-OHD) concentrations lower than 20 ng\u002FmL (50 nmol\u002FL)",{"count":49,"type":22},125,"A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral alendronate following denosumab",[26],{"date":30,"type":31},{"date":54,"type":31},"2023-11-28",{"date":56,"type":22},"2027-11",{"name":37,"class":38},9,""]